Research SummaryKey Findings

What research findings exist on KPV regarding inflammation and the intestinal mucosal barrier?

ProKPV responsive to inflammation improves delivery and enhances anti-inflammatory effects. Another study reports that KPV co-assembled with FK506 nanoparticles improves inflammation and intestinal barrier.[1] ↗ [2] ↗

Before ReadingStudy populations, species, formulations and delivery conditions each have a defined scope. Research on an ingredient does not establish that this site's product batches have been validated for efficacy in humans or veterinary use.
i

Currently, 3 original studies related to the theme of this page have been selected. The number of studies includes different designs, populations, or preparations, not commercial clinical efficacy ratings. This page is a usage-oriented positive data selection, not a systematic review or dosing recommendation. Historical studies, combination preparations, and special models are all separately indicated.

Comparison of study design and results

Results from different populations, species, materials, or follow-up times cannot be directly combined. The table below is a comparative summary of published data, not new experimental data.

LiteratureStudy subjects and designObservation and discoveryScope of Explanation
2026 · PMID 41533788Mouse colitis and acute lung injury; KPV prodrugProKPV that responds to inflammation improves delivery and enhances anti-inflammatory effects.Studies a chemically modified prodrug, not the prototype KPV direct administration.
2024 · PMID 39211778DSS mice acute/chronic colitisKPV co-assembled with FK506 nanoparticles improves inflammation and intestinal barrier.Combined immunosuppressants and nano-delivery.
2022 · PMID 35245681TNBS rat colitis; intrarectal administrationPMSP-KPV hydrogel enhances local anti-inflammatory effects and mucosal barrier restoration.Materials combined with delivery cannot be used as clinical evidence for regular KPV injections.

References

Animal Study2026REF. 01

How is the prodrug KPV studied for intestinal delivery and inflammation?

Research Findings

ProKPV that responds to inflammation improves delivery and enhances anti-inflammatory effects.[1] ↗

Study Design

Mouse colitis and acute lung injury; KPV prodrug

Scope & Limitations

Studies a chemically modified prodrug, not the prototype KPV direct administration.

View the Article Title and Full Citation＋

Inflammation-triggered self-immolative conjugates enable oral peptide delivery by overcoming gastrointestinal barriers.

Cheng J, Wu P, Li C, Han Y, Sun M, Dou Y, Chen S, Zhang J.

Science Advances · Volume/Issue/Year 2026
First published 2026-01-14 · PMID 41533788
DOI 10.1126/sciadv.aea2989

Published · Original ResearchPubMed ↗Journal Article ↗
Animal Study2024REF. 02

What research findings exist for KPV co-assembled with immunosuppressants?

Research Findings

KPV co-assembled with FK506 nanoparticles improves inflammation and intestinal barrier.[2] ↗

Study Design

DSS mice acute/chronic colitis

Scope & Limitations

Combined immunosuppressants and nano-delivery.

View the Article Title and Full Citation＋

PepT1-targeted nanodrug based on co-assembly of anti-inflammatory peptide and immunosuppressant for combined treatment of acute and chronic DSS-induced ColitiS.

Zhang D, Jiang L, Yu F, Yan P, Liu Y, Wu Y, Yang X.

Frontiers in Pharmacology · Volume and Issue Year 2024
First published 2024-08-15 · PMID 39211778
DOI 10.3389/fphar.2024.1442876

Published · Original ResearchPubMed ↗Journal Article ↗
Animal Study2022REF. 03

What does research on KPV combined with hydrogels indicate about the intestinal barrier?

Research Findings

PMSP-KPV hydrogel enhances local anti-inflammatory effects and mucosal barrier restoration.[3] ↗

Study Design

TNBS rat colitis; intrarectal administration

Scope & Limitations

Materials combined with delivery cannot be used as clinical evidence for regular KPV injections.

View the Article Title and Full Citation＋

A KPV-binding double-network hydrogel restores gut mucosal barrier in an inflamed colon.

Zhao Y, Xue P, Lin G, Tong M, Yang J, Zhang Y, Ran K, Zhuge D, Yao Q, Xu H.

Acta Biomaterialia · Volume/Issue, 2022
First published 2022-03-01 · PMID 35245681
DOI 10.1016/j.actbio.2022.02.039

Published · Original ResearchPubMed ↗Journal Article ↗

Common issues and corresponding evidence

What research findings exist on KPV regarding inflammation and the intestinal mucosal barrier?＋

ProKPV responsive to inflammation improves delivery and enhances anti-inflammatory effects. Another study reports that KPV co-assembled with FK506 nanoparticles improves inflammation and intestinal barrier.[1] ↗ [2] ↗

Do all intestinal barrier studies of KPV use regular KPV?＋

No. Current data includes prodrugs, combined immunosuppressants, and hydrogel delivery, and should be interpreted separately; it cannot be regarded as the human efficacy of unmodified KPV injection.[1] ↗ [2] ↗ [3] ↗

KPV—these conclusions apply to which study populations?＋

Mouse colitis and acute lung injury; KPV prodrug; DSS mouse acute/chronic colitis; TNBS rat colitis; intracolonic administration. The study is on chemically modified prodrugs, not direct administration of the prototype KPV.[1] ↗ [2] ↗ [3] ↗

KPV

Return to catalog specifications and batch file verification entry.

↗